These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 28263048)

  • 1. Pancreatic beta cell function is preserved in the short term in patients with type 2 diabetes undergoing non-urgent surgery.
    Hernanz-Rodriguez G; Pedrianes-Martin P; de Pablos-Velasco P; Rodriguez-Perez A
    Minerva Endocrinol; 2018 Jun; 43(2):109-116. PubMed ID: 28263048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decrement of postprandial insulin secretion determines the progressive nature of type-2 diabetes.
    Shim WS; Kim SK; Kim HJ; Kang ES; Ahn CW; Lim SK; Lee HC; Cha BS
    Eur J Endocrinol; 2006 Oct; 155(4):615-22. PubMed ID: 16990662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium-glucose cotransporter-2 inhibition improves incretin sensitivity of pancreatic β-cells in people with type 2 diabetes.
    Ahn CH; Oh TJ; Kwak SH; Cho YM
    Diabetes Obes Metab; 2018 Feb; 20(2):370-377. PubMed ID: 28786557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Restoration of the insulinotropic effect of glucose-dependent insulinotropic polypeptide contributes to the antidiabetic effect of dipeptidyl peptidase-4 inhibitors.
    Aaboe K; Akram S; Deacon CF; Holst JJ; Madsbad S; Krarup T
    Diabetes Obes Metab; 2015 Jan; 17(1):74-81. PubMed ID: 25243647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beta-cell function and mass in type 2 diabetes.
    Larsen MO
    Dan Med Bull; 2009 Aug; 56(3):153-64. PubMed ID: 19728971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Saxagliptin improves glycemic control by modulating postprandial glucagon and C-peptide levels in Chinese patients with type 2 diabetes.
    Sjöstrand M; Iqbal N; Lu J; Hirshberg B
    Diabetes Res Clin Pract; 2014 Aug; 105(2):185-91. PubMed ID: 24947443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impaired beta-cell sensitivity to glucose and maximal insulin secretory capacity in adolescents with type 2 diabetes.
    Elder DA; Woo JG; D'Alessio DA
    Pediatr Diabetes; 2010 Aug; 11(5):314-21. PubMed ID: 19961550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beta-cell response to intravenous glucagon in African-American and Hispanic children with type 2 diabetes mellitus.
    Taha DR; Castells S; Umpaichitra V; Bastian W; Banerji MA
    J Pediatr Endocrinol Metab; 2002 Jan; 15(1):59-67. PubMed ID: 11822582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fasting serum total bile acid levels are associated with insulin sensitivity, islet β-cell function and glucagon levels in response to glucose challenge in patients with type 2 diabetes.
    Wang XH; Xu F; Cheng M; Wang X; Zhang DM; Zhao LH; Cai HL; Huang HY; Chen T; Zhang XL; Wang XQ; Cheng XB; Su JB; Lu Y
    Endocr J; 2020 Nov; 67(11):1107-1117. PubMed ID: 32684527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term intensive insulin therapy could be the preferred option for new onset Type 2 diabetes mellitus patients with HbA1c > 9.
    Weng J
    J Diabetes; 2017 Oct; 9(10):890-893. PubMed ID: 28661564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential effects of ambient blood glucose level and degree of obesity on basal serum C-peptide level and the C-peptide response to glucose and glucagon in non-insulin-dependent diabetes mellitus.
    Park SW; Ihm SH; Yoo HJ; Park JY; Lee KU
    Diabetes Res Clin Pract; 1997 Sep; 37(3):165-71. PubMed ID: 9306037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C-peptide concentrations in patients with type 2 diabetes treated with insulin.
    Uzunlulu M; Oguz A; Arslan Bahadir M; Erbakan AN; Vural Keskinler M; Alpaslan Mesci B
    Diabetes Metab Syndr; 2019; 13(6):3099-3104. PubMed ID: 31785503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of glargine versus glimepiride on pancreatic β-cell function in patients with type 2 diabetes uncontrolled on metformin monotherapy: open-label, randomized, controlled study.
    Moon JS; Ha KS; Yoon JS; Lee HW; Lee HC; Won KC;
    Acta Diabetol; 2014 Apr; 51(2):277-85. PubMed ID: 24445656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DPP-4 inhibitor treatment: β-cell response but not HbA
    Kozlovski P; Bhosekar V; Foley JE
    Vasc Health Risk Manag; 2017; 13():123-126. PubMed ID: 28408838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of saxagliptin on β-cell stimulation and insulin secretion in patients with type 2 diabetes.
    Henry RR; Smith SR; Schwartz SL; Mudaliar SR; Deacon CF; Holst JJ; Duan RY; Chen RS; List JF
    Diabetes Obes Metab; 2011 Sep; 13(9):850-8. PubMed ID: 21554520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ketosis onset type 2 diabetes had better islet β-cell function and more serious insulin resistance.
    Lu H; Hu F; Zeng Y; Zou L; Luo S; Sun Y; Liu H; Sun L
    J Diabetes Res; 2014; 2014():510643. PubMed ID: 24829925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of once weekly dulaglutide by baseline beta-cell function in people with type 2 diabetes in the AWARD programme.
    Mathieu C; Del Prato S; Botros FT; Thieu VT; Pavo I; Jia N; Haupt A; Karanikas CA; García-Pérez LE
    Diabetes Obes Metab; 2018 Aug; 20(8):2023-2028. PubMed ID: 29603872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of incretin-based therapies on β-cell function and insulin resistance in type 2 diabetes: A systematic review and network meta-analysis combining 360 trials.
    Wu S; Gao L; Cipriani A; Huang Y; Yang Z; Yang J; Yu S; Zhang Y; Chai S; Zhang Z; Sun F; Zhan S
    Diabetes Obes Metab; 2019 Apr; 21(4):975-983. PubMed ID: 30536884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-sectional and Longitudinal Analyses of Factors Contributing to the Progressive Loss of the β-cell Function in Type 2 Diabetes.
    Nakayama H; Kato T; Nakayama S; Kaku H; Muraishi K; Tokubuchi I; Hara K; Kato T; Wada N; Tsuruta M; Ohki T; Tanaka K; Mitsuzaki K; Tajiri Y; Yamada K
    Intern Med; 2015; 54(16):1971-6. PubMed ID: 26278286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preserved Insulin Secretory Capacity and Weight Loss Are the Predominant Predictors of Glycemic Control in Patients With Type 2 Diabetes Randomized to Roux-en-Y Gastric Bypass.
    Nguyen KT; Billington CJ; Vella A; Wang Q; Ahmed L; Bantle JP; Bessler M; Connett JE; Inabnet WB; Thomas A; Ikramuddin S; Korner J
    Diabetes; 2015 Sep; 64(9):3104-10. PubMed ID: 25901097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.